Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has a historical diagnosis of Type 2 Diabetes Mellitus.~* Has a body mass index between acceptable range.~* Is experiencing inadequate glycemic control.~* Body weight keeps constant.~* Females of childbearing potential and males who are sexually active agree to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.~Exclusion Criteria:~* Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.~* Has a systolic blood pressure beyond the acceptable range at Screening visit.~* Has New York Heart Association Class III or IV heart failure regardless of therapy.~* Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.~* Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
- Alogliptin Monotherapy (Type: EXPERIMENTAL): Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
- Metformin (Type: OTHER): Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
- Metformin + Alogliptin Add-on Therapy (Type: EXPERIMENTAL): Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
- Pioglitazone (Type: OTHER): Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
- Pioglitazone + Alogliptin Add-on Therapy (Type: EXPERIMENTAL): Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).